Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Buspirone Launch Awaits Bristol Appeal Of BuSpar Patent Order

Executive Summary

Bristol-Myers Squibb appears to have at least two more chances to block a generic version of BuSpar from coming to market following a March 13 preliminary injunction imposed by Judge Ricardo Urbina in Washington, D.C. federal court.
Advertisement

Related Content

BuSpar Antitrust Suit Will Test Theory Of “Orange Book” Abuse
BuSpar Appeal: Bristol Argues Mylan Evaded Waxman/Hatch By Filing Suit
GSK Paxil NDA Covers Hemihydrate And Anhydrous Paroxetine, Company Says
FTC Asks FDA To Clarify "Orange Book" Listing Criteria In Citizen Petition
Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market
AstraZeneca Awaits "Orange Book" Listing For Three Prilosec Patents
Bristol HIV Price Cut Includes Pledge Not To Enforce Patent Rights In Africa
AstraZeneca Awaits "Orange Book" Listing For Three Prilosec Patents
Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
Bristol BuSpar Metabolite Patent Issued One Day Before Watson Generic
Advertisement
UsernamePublicRestriction

Register

PS037517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel